Welcome to our dedicated page for Rani Therapeutics Holdings SEC filings (Ticker: RANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Rani Therapeutics Holdings, Inc. filings document the regulatory record of a clinical-stage biotherapeutics company developing oral delivery technology for biologics and drugs. Form 8-K reports include quarterly and annual financial results, corporate updates, clinical and preclinical program disclosures, collaboration and license matters, and material agreements affecting the company’s operations and strategy.
The filing record also covers capital-structure activity involving Class A common stock, common warrants and pre-funded warrants, as well as Nasdaq continued-listing compliance notices. Proxy materials describe annual meeting matters, board elections, auditor ratification, governance procedures and stockholder voting mechanics for RANI’s public-company structure.
Rani Therapeutics (Nasdaq:RANI) filed an 8-K disclosing receipt of a Nasdaq minimum-bid-price deficiency notice. The stock closed below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).
The Company has 180 days, until December 17 2025, to lift its bid to at least $1.00 for 10 straight sessions. If unsuccessful, Rani may seek a second 180-day grace period by moving to the Nasdaq Capital Market and, if needed, enacting a reverse stock split. Failure to regain compliance would result in delisting.
Management is monitoring the share price and evaluating alternatives but gives no assurance of success. Liquidity, investor base and valuation could be materially affected if the listing is lost.